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Abstract: Skin infiltration of circulating memory T cells with
cutaneous tropism is considered one of the pathologic mechanisms
in atopic dermatitis (AD). Skin-seeking circulating T lymphocytes
can be identified by their expression of the cutaneous lymphocyte-
associated antigen on the cell surface. Recent studies have contrib-
uted useful new information about the function and recirculation
properties of those cells in AD patients. This review integrates the
latest findings on peripheral cutaneous lymphocyte-associated anti-
gen memory T cells in AD and highlights the relevance of this cell
type and its importance to our understanding of the pathologic
mechanisms of AD.
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INTRODUCTION
Atopic dermatitits (AD) is the most common childhoodskin disease, with a steadily increasing prevalence over
recent decades. Characterized by chronic and relapsing flares
of intrinsic or extrinsic eczema, AD is considered to be part
of the atopic state, which includes asthma, allergic rhinitis,
allergic conjunctivitis, and food allergies. AD normally pre-
cedes all of these conditions.1 The exact etiopathogenic
mechanisms are unknown but genetics, immunologic, and
environmental factors have been involved, and defects in skin
barrier function.2 Our understanding of AD pathogenesis
expanded with the recent identification of its association with
loss-of-function mutations in filaggrin, an epidermal protein
important for cutaneous barrier integrity. These mutations
produce a heritable epithelial barrier dysfunction that allows
allergens and microbes easy access; this may cause a polar-
ized TH2 lymphocyte response, which results in eczema.2
However, it has also been suggested that TH2 cytokines could
influence barrier function, modulating the expression of filag-
grin or other structural proteins and peptides important for
microbial barrier function.3 Without taking into account their
primary or secondary role in the defective barrier function in
AD, it is known that T cells play an important role in the
pathologic mechanism of AD. The fact that drugs acting on
immune-mediated mechanisms are the most effective treat-
ments for AD at the moment (corticosteroids and immuno-




Circulating memory cutaneous lymphocyte-associated
antigen (CLA) T cells participate in the inflammatory reac-
tion produced during the initiation of AD lesion.4–6 Recent
studies, reviewed below, support the role of CLA T cells as
one of the pathologic mechanisms in AD, and the reduced
innate immune response and abnormal skin barrier function.2
CLA, a surface glycoprotein expressed in 15% of
peripheral blood lymphocytes, acts as a skin homing mole-
cule.7,8 CLA is expressed in 90% of infiltrating T cells
present in inflamed skin, but is found in 20% of T lympho-
cytes in other inflamed sites such as gut, joints, or lungs.9
CLA is a carbohydrate posttranslational modification of
the ubiquitously expressed p-selectin glycoprotein ligand-1
(PSGL-1) by the enzymatic activity of fucosyltransferase VII
(FucT-VII).10 Interleukin (IL)-12, which drives naive T cells
into TH1 cell differentiation, is also the best characterized
mediator responsible for conferring skin homing to both TH1
and TH2 cells, by inducing FucT-VII.5 Superantigens may
have a role in the induction of CLA expression in certain
disorders such as AD.11 At present, it is believed that tissue-
specific homing receptors are imprinted on T cells in tissue-
draining lymph nodes. This is best demonstrated by homing
markers for the gut and skin by gut-draining lymph nodes and
skin-draining lymph nodes, respectively. Dendritic cells and
soluble factors are believed to mediate this immunologic
imprinting.12–14
Significant experimental and clinical results support the
concept that leukocyte migration to tissues under inflamma-
tory conditions is not a random process but rather is orches-
trated through molecules such as adhesion molecules and
chemokines.7 The CLA antigen is part of a complex multistep
molecular interaction between circulating lymphocytes and
cutaneous vascular endothelium that takes place during lym-
phocyte migration to the skin. Under inflammatory condi-
tions, proinflammatory mediators like IL-1 and tumor necro-
sis factor (TNF)- up-regulate the expression of adhesion
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molecules on the surface of endothelial cells. In inflammation,
the interactions between CLA/E-selectin, Very Late Antigen-
4(VLA-4)/Vascular Cell Adhesion Molecule-1(VCAM-1) and
Lymphocyte Function-Associated Antigen-1(LFA-1)/Inter-
Cellular Adhesion Molecule 1 (ICAM-1) are required in the
transendothelial migration of CLA T cells.15
CLINICAL RELEVANCE OF CUTANEOUS
CHEMOKINES THAT ATTRACT CIRCULATING
CLA T CELLS TO INFLAMED SKIN IN AD
Besides the array of adhesion molecules implicated in T
cell transendothelial migrations, circulating CLA T cells
require chemo-attractant stimuli, provided by specific chemo-
kines, to reach the inflamed skin. It is known that the
chemokine receptors CCR4 and CCR10 are highly expressed
on circulating CLA T cells.4,16,17 Thymus and activation-
regulated chemokine (TARC/CCL17) and macrophage-de-
rived chemokine (MDC/CCL22) are the chemokines ligands
specific for CCR4, whereas the cutaneous T cell-attracting
chemokine (CTACK/CCL27) is specific for CCR10.18 The
production of MDC, TARC, and CTACK is well established
in AD lesions,19 and recent studies have correlated the ex-
pression of these chemokines/chemokine receptors involved
in CLA T cell chemotaxis with clinical severity of AD. In
addition, cutaneous CCL18 is associated with AD, which
mediates skin homing of human memory T cells.20,21
TARC is expressed by keratinocytes, vascular endothe-
lial cells, T cells, and dendritic cells.22 Intradermal injection
of TARC into human skin grafted on severe combined im-
munodeficient (SCID) mice reconstituted with peripheral
blood mononuclear cells results, 24 hours later, in a cutane-
ous recruitment of human memory CD4() cells, monocytes,
and basophiles, but also murine eosinophils. In SCID mice
reconstituted with polarized Th-1 or Th-2 cells, intradermal
injection of TARC resulted in the recruitment of IL-4()
Th-2 cells but not of IFN-() Th-1 cells.4,23 In AD patients,
TARC/CCL17 levels are significantly higher than those of
healthy control subjects and patients with psoriasis. Increased
serum TARC levels in AD patients decreases after treatment,
in accordance with improvement in clinical symptoms. Fur-
thermore, an association between serum levels and AD dis-
ease activity has been found.24
MDC is produced by macrophages and dendritic cells
upon activation and its serum levels are higher in AD patients
than in healthy controls and psoriasis patients.25 Increases in
serum MDC levels are greater in severe AD patients than in
moderate or mild AD cohorts, decrease after treatment, and
significantly correlates with the Scoring AD (SCORAD)
index25 and CCL18.21 Interestingly, the CCR4 receptor,
which binds both MDC and TARC, is preferentially ex-
pressed on CD4 T cells from AD patients. The expression of
CCR4 is more prominent in severe AD subjects and decreases
when disease activity improves.26
Finally, CTACK is produced by basal keratinocytes;17
the serum levels of this chemokine in patients with AD are
significantly higher than in healthy control subjects, and
correlate with SCORAD.27 A differential gene expression
study comparing peripheral blood CD4 T cells from AD
patients and healthy controls identified increased expression
of some genes in AD patients. Some of those genes were
associated to tissue homing, such as CCR10, the specific
receptor for CCL27.28 The FucT VII CLA TH2 subset,
which has the most potent capacity to bind E-selectin, in-
creased dramatically in the blood of AD patients. This in-
crease was related to the severity of clinical symptoms.29
All together, these studies suggest a correlation be-
tween AD severity and serum levels of CLA T cell-attract-
ing chemokines such as MDC, TARC, and CTACK, which
can be reduced with treatment. Because inflamed skin is the
source of these mediators, one possible chemokine mecha-
nism is to attract circulating CLA T cells to the inflamma-
tory focus. This is not a mere infiltration process of T cells
into the skin. When all the pieces of information about CLA
T cells are put together, a clearer picture emerges of the
relevance of chemokines-attracting skin-homing T cells to
disease severity.
CIRCULATING CLA T CELLS CONTAIN
SUBSETS OF T CELLS THAT RESPOND TO
CUTANEOUS ALLERGENS
The CLA antigen is not expressed on naive CD45RA
cells, but rather on a subset of antigen-experienced memory
effector T cells.30 Memory effector T cells constitute a
subpopulation of lymphocytes able to produce a wide range
of cytokines that are involved in inflammation. It is well
established that only CLA T cells from AD patients, but not
asthmatics or healthy controls, preferentially respond to cu-
taneous allergens such as Dermatophagoides pteronyssinus in
AD.31 Thus, in AD the CLA T cell-attracting chemokines
are involved in the migration of circulating allergen-experi-
enced T cells to skin. One possible hypothesis is that under
such circumstances increased trafficking of allergen-specific
T cells from blood to skin takes place, resulting in a corre-
lation between serum levels of chemokines and disease se-
verity. Furthermore, skin-infiltrating CLA T cells not only
respond to cutaneous allergens in AD, but are also exposed to
microorganisms that can cause cutaneous infection, such as
Staphylococcus aureus (S. aureus). Cutaneous infections in
AD are a common event that exacerbates the disease.32
Patients with active AD present a higher percentage of cells
positive for the T cell receptor (TCR) V2 and V5.1
segments in the CLA but not in the CLA subset.33 Thus,
chemokines-attracting CLA T cells will contribute to the
infiltration mechanism of allergen-specific and S. aureus
superantigen-responsive T cells that could boost allergic
inflammation in AD.
The use of biologic treatments that are specifically
directed toward relevant molecules involved in lymphocyte
trafficking offers opportunities to understand the pathologic
mechanism in AD. This is the case of efalizumab, an anti-
LFA-1 antibody. LFA-1, an adhesion molecule of the integrin
family, binds to ICAM-1 on endothelial cells and mediates
leukocyte extravasation. Furthermore, LFA-1 is involved in
CLA T cell dependent transendothelial migration.34 Lesions
improved in AD patients treated with efalizumab; at the same
time, patients presented a marked increase in circulating
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memory CD4 T cells that express the CLA antigen.15 One
possible explanation for this effect would be a continuous
recirculation of CLA T cells between skin lesions and
peripheral blood: when LFA-1 is blocked, CLA T cells from
the skin accumulate in circulation.34 Although these CLA T
cells are effector memory T cells, it appears that circulating T
cells from AD patients present decreased expression of ap-
optosis-related genes compared with the same subtype in
healthy individuals, indicating a prolonged survival.34 In
support of the recirculation hypothesis, some activation
markers (HLA-DR, CD25, and CD69) are expressed in
CLA T cells present in peripheral blood.31,35 In addition, it
has been shown that circulating CLA T cells in AD spon-
taneously produce TH2 cytokines (IL-4, IL-5, and IL-13)
without need of TCR activation,31,36 suggesting that those
cells have been previously activated.
Recently, the implication of CLA T cell function in
AD has also expanded to itching. IL-31 is a newly identified
cytokine that when overexpressed in mice induces pruritus,37
providing a new link between CLA T cells and itching in
AD patients. IL-31 is produced by activated T lymphocytes,
and preferentially by TH2 cells. In vivo application of Staph-
ylococcal superantigen to skin can rapidly induce IL-31 in
atopic individuals and its receptor presents the most abundant
expression in dorsal root ganglia, the anatomic location of the
cell bodies of cutaneous sensory neurons.38 In addition, IL-31
receptor is also expressed by keratinocytes and macrophages.
Human keratinocytes activated by IL-31 produce different
types of chemokines, such as TARC (CCL17) and MDC
(CCL22).37 IL-31 is exclusively produced by circulating
CLA T cells, and superantigen enterotoxin B activation of
peripheral blood lymphocytes induced production of IL-31.38
Recent findings suggest IL-31 antibody as a new potential
therapeutic approach for pruritus in AD and other pruritic
diseases. Finally, other neurogenic mechanisms involve
CLA T cells in AD. Calcitonin gene-related peptide has
been shown to directly activate CLA T cells and increase
IL-13 production in AD patients,39 and mental stress in AD
increased the number of CLA T cells in circulation.40
CIRCULATION OF CLA T CELLS IN AD
In summary, circulating CLA T cells with potential to
recognize allergens related to AD and bacterial infections are
present in peripheral blood. T lymphocytes with skin tropism
are attracted into the cutaneous inflammatory focus through
adhesion molecules expressing endothelial cells (E-selectin,
VCAM-1, and ICAM-1) and the production of chemokines
MDC, TARC, CTACK, and CCL18. There is a relationship
between clinical severity and the presence of CLA T cell-
attracting chemokines in the serum, suggesting that continu-
ous T cell infiltration may take place during cutaneous in-
flammation.
In acute AD, circulating CLA T cells preferentially
express TH2 cytokines (IL-4, IL-5, and IL-13) in comparison
to controls or CLA-negative cells. In addition, CLA T cells
produce IL-31 upon activation, which links this skin-homing
population to itching in AD. As shown in Figure 1, it can be
hypothesized that CLA T cells recirculate between blood
and inflamed lesions in AD, similar to the dynamics of
memory T cell recall response in peripheral tissue.8
Peripheral CLA T cells express activation markers
and reduced levels of apoptosis-related genes in AD patients,
and spontaneously produce cytokines also detected in skin
lesions. An anti-LFA-1 antibody that has been shown to
interfere with T cell memory trafficking into skin may induce
CLA T cells lymphocytosis. Recirculation between skin and
blood could persist for as long as the attracting gradient and
adhesion molecules specific for CLA are present in the
lesions. Once a lesion improves, a pool of circulating CLA
T cells with skin-homing potential that can participate in
future allergic inflammation is present in the blood of AD
patients, by virtue of the memory pool generated during
inflammation.
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